Table I.
Sequences of primers used.
| A, Med IP assay | ||
|---|---|---|
| Target | Primer sequence (5′-3′) | Length of PCR products |
| ACSS2 | CCCAGACCATAACAGTACCGACTC | 294 |
| CGCCTTTGCCATTCATAGAGC | ||
| BDNF | TTAGAGGAGGTGTAGCCTTGTT | 223 |
| TTGTCATCACAGTGGGAAGC | ||
| CCL2 | AAAGTTTCCATTGCTGCTGCTC | 106 |
| TCTGATGTAACGGGCTCTTGG | ||
| FAS | ACTTCCCTACCCACCCATTC | 220 |
| AAAGTACCCAAGGAGCTAAAGG | ||
| GCR | ATTGCCCTGGATGCCTGTAA | 321 |
| ATGACCATGAACCTCCTGAA | ||
| GDNF | ATGGCTCTATGCTGCTTTGC | 163 |
| TATCCCAGACGTGGACTTGC | ||
| GLUR2 | GAGGGTGGAATGGGAAAGAG | 197 |
| AGGCAGCTACCAAATGTCTCG | ||
| HMGB1 | TTTTCCTTCTTTGGGTCTAA | 217 |
| CCAGCCTAACTCTGCTTCCT | ||
| MMP9 | TGGTTTCAGAAGAGGAGGACAGG | 248 |
| GCAGCGAGGAACAGGGAGCA | ||
| B, qPCR assay | ||
| Target | Primer sequence (5′-3′) | Length of PCR products |
| ACSS2 | TCCCATTCTTCGGTGTAGCG | 376 |
| GTAACAAAGCAGTAGAGGCATTCG | ||
| BNDF | GTGGGTCACAGCGGCAGATA | 203 |
| ACGATTGGGTAGTTCGGCATT | ||
| CCL2 | AAGAAGGAATGGGTCCAGACA | 140 |
| GCTTCAGATTTACGGGTCAACT | ||
| FAS | TCTGGGCTGTCCTGCCTCTG | 111 |
| CAGTTTCACGAACCCGCCTC | ||
| GCR | TGGAATAGGTGCCAAGGGTC | 171 |
| GCAGAGTTTGGGAGGTGGTC | ||
| GDNF | GATGAAGTTATGGGATGTCGTGG | 175 |
| TGCCGCTTGTTTATCTGGTGA | ||
| GLUR2 | GAAGCCTCAGAAGTCCAAACC | 342 |
| TTAGCCGTGTAGGAGGAGATG | ||
| HMGB1 | ATCCTGGCTTATCCATTGGTG | 244 |
| TCCTCATCCTCTTCATCCTCCT | ||
| MMP9 | AAGGGTACAGCCTGTTCCTGGTG | 146 |
| GATGCCGTCTATGTCGTCTTTATTCA | ||
MedIP, methylated DNA immunoprecipitation; ACSS2, acyl-CoA synthetase short chain family member 2; BDNF, brain derived neurotrophic factor; CCL2, C-C motif chemokine ligand 2; FAS, fas cell surface death receptor; GCR, glucocorticoid receptor; GDNF, glial cell-derived neurotrophic factor; GluR2, glutamate receptor 2 precursor; HMGB1, high mobility group protein B1; q, quantitative; MMP9, matrixmetallopeptidase-9.